Cure8 trial brief
A pediatric trial of budesonide rectal foam could provide evidence about a locally acting steroid option for children with distal ulcerative colitis. Trial results may affect treatment choices for pediatric distal disease.
Parents and caregivers of children (5–17 years) with mild-to-moderate distal ulcerative colitis; pediatric gastroenterologists and IBD researchers interested in topical steroid therapies and pediatric trials.
This ClinicalTrials.gov record describes a dose-ranging, not-yet-recruiting study sponsored by Bausch Health Americas. The primary objective is induction of remission comparing low and high doses by age group.
Eligibility exclusions listed include recent infectious colitis, most prior GI surgeries, toxic megacolon or bowel resection, and active proctologic problems that would interfere with rectal administration. The listing is a trial record (not results). It describes study design and key eligibility but does not provide outcomes or safety findings.
If you or your child are considering trial participation, discuss with your gastroenterology team — this registry entry is a starting point to learn more from the study team.
This is a ClinicalTrials.gov trial record (Phase 4, not yet recruiting) that describes planned interventions and eligibility but does not report study results. Registry entries can change; contact the study sponsor or site for up-to-date recruitment and protocol details.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
This trial investigates a new oral medication (PALI-2108) for moderate-to-severe ulcerative colitis and could expand treatment options if later trials show benefit and safety. The study focuses on clinical remission at...
Pediatric-onset IBD can behave differently than adult-onset disease. Comparing conventional versus biologic approaches in children may help clarify relative effectiveness, safety, and impacts on growth and steroid...
Patients with ulcerative colitis and their clinicians may be interested because the study tests whether adding pentoxifylline to standard mesalamine improves disease activity measured by the Mayo Score over 6 months.
